REVIEW article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1576781
This article is part of the Research TopicNovel Molecular Targets in Cancer TherapyView all 40 articles
Advances of HDAC Inhibitors in Tumor Therapy: Potential Applications Through Immune Modulation
Provisionally accepted
- 1Department of Pathology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan Province, China
- 2Xinxiang Central Hospital, Xinxiang, Henan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Histone deacetylase inhibitors (HDAC inhibitors, HDACi) have garnered considerable attention due to their potential in treating various types of malignant tumors. Histone deacetylases (HDACs) not only influence chromatin structure and gene transcription by regulating histone acetylation status but also acetylate various nonhistone proteins. They are widely involved in several key biological processes, such as cell cycle regulation, apoptosis induction, and immune responses. HDACi exert their effects by inhibiting HDAC activity; however, these effects are highly concentrationdependent and non-selective. HDACi inevitably disrupt both gene expression and signaling networks, leading to multi-target, non-specific biological effects. This article focuses on the immunomodulatory mechanisms of HDACi, including their role in remodeling the tumor extracellular matrix and their impact on various immune cell populations. The synergistic potential of combining HDACi with other therapeutic approaches is also discussed. This review examines the application of HDACi across different tumor types, highlighting preclinical and clinical evidence that demonstrates the multifunctionality and efficacy of HDACi. By leveraging their unique mechanism of action, HDACi opens new avenues for enhancing antitumor immunity and achieving durable therapeutic responses. Future research and clinical trials will play a crucial role in optimizing the use of HDACi, elucidating resistance mechanisms, and identifying the most effective combinations to maximize patient benefit.
Keywords: HDACi, tumor therapy, Immunotherapy, Tumor Microenvironment, combination therapy
Received: 14 Feb 2025; Accepted: 16 Jun 2025.
Copyright: © 2025 Tian, Han, Song, Liu, Shen and Zhong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yuhou Shen, Xinxiang Central Hospital, Xinxiang, Henan Province, China
Jiateng Zhong, Department of Pathology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.